Amos L

References (2)

Title : Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study - Davidson_2012_Alzheimers.Res.Ther_4_51
Author(s) : Davidson JE , Lockhart A , Amos L , Stirnadel-Farrant HA , Mooser V , Sollberger M , Regeniter A , Monsch AU , Irizarry MC
Ref : Alzheimers Res Ther , 4 :51 , 2012
Abstract : INTRODUCTION: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a circulating enzyme with pro-inflammatory and oxidative activities associated with cardiovascular disease and ischemic stroke. While high plasma Lp-PLA2 activity was reported as a risk factor for dementia in the Rotterdam study, no association between Lp-PLA2 mass and dementia or Alzheimer's disease (AD) was detected in the Framingham study. The objectives of the current study were to explore the relationship of plasma Lp-PLA2 activity with cognitive diagnoses (AD, amnestic mild cognitive impairment (aMCI), and cognitively healthy subjects), cardiovascular markers, cerebrospinal fluid (CSF) markers of AD, and apolipoprotein E (APOE) genotype.
METHODS: Subjects with mild AD (n = 78) and aMCI (n = 59) were recruited from the Memory Clinic, University Hospital, Basel, Switzerland; cognitively healthy subjects (n = 66) were recruited from the community. Subjects underwent standardised medical, neurological, neuropsychological, imaging, genetic, blood and CSF evaluation. Differences in Lp-PLA2 activity between the cognitive diagnosis groups were tested with ANOVA and in multiple linear regression models with adjustment for covariates. Associations between Lp-PLA2 and markers of cardiovascular disease and AD were explored with Spearman's correlation coefficients.
RESULTS: There was no significant difference in plasma Lp-PLA2 activity between AD (197.1 (standard deviation, SD 38.4) nmol/min/ml) and controls (195.4 (SD 41.9)). Gender, statin use and low-density lipoprotein cholesterol (LDL) were independently associated with Lp-PLA2 activity in multiple regression models. Lp-PLA2 activity was correlated with LDL and inversely correlated with high-density lipoprotein (HDL). AD subjects with APOE-epsilon4 had higher Lp-PLA2 activity (207.9 (SD 41.2)) than AD subjects lacking APOE-epsilon4 (181.6 (SD 26.0), P = 0.003) although this was attenuated by adjustment for LDL (P = 0.09). No strong correlations were detected for Lp-PLA2 activity and CSF markers of AD. CONCLUSION: Plasma Lp-PLA2 was not associated with a diagnosis of AD or aMCI in this cross-sectional study. The main clinical correlates of Lp-PLA2 activity in AD, aMCI and cognitively healthy subjects were variables associated with lipid metabolism.
ESTHER : Davidson_2012_Alzheimers.Res.Ther_4_51
PubMedSearch : Davidson_2012_Alzheimers.Res.Ther_4_51
PubMedID: 23217243

Title : Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study - Kasperaviciute_2010_Brain_133_2136
Author(s) : Kasperaviciute D , Catarino CB , Heinzen EL , Depondt C , Cavalleri GL , Caboclo LO , Tate SK , Jamnadas-Khoda J , Chinthapalli K , Clayton LM , Shianna KV , Radtke RA , Mikati MA , Gallentine WB , Husain AM , Alhusaini S , Leppert D , Middleton LT , Gibson RA , Johnson MR , Matthews PM , Hosford D , Heuser K , Amos L , Ortega M , Zumsteg D , Wieser HG , Steinhoff BJ , Kramer G , Hansen J , Dorn T , Kantanen AM , Gjerstad L , Peuralinna T , Hernandez DG , Eriksson KJ , Kalviainen RK , Doherty CP , Wood NW , Pandolfo M , Duncan JS , Sander JW , Delanty N , Goldstein DB , Sisodiya SM
Ref : Brain , 133 :2136 , 2010
Abstract : Partial epilepsies have a substantial heritability. However, the actual genetic causes are largely unknown. In contrast to many other common diseases for which genetic association-studies have successfully revealed common variants associated with disease risk, the role of common variation in partial epilepsies has not yet been explored in a well-powered study. We undertook a genome-wide association-study to identify common variants which influence risk for epilepsy shared amongst partial epilepsy syndromes, in 3445 patients and 6935 controls of European ancestry. We did not identify any genome-wide significant association. A few single nucleotide polymorphisms may warrant further investigation. We exclude common genetic variants with effect sizes above a modest 1.3 odds ratio for a single variant as contributors to genetic susceptibility shared across the partial epilepsies. We show that, at best, common genetic variation can only have a modest role in predisposition to the partial epilepsies when considered across syndromes in Europeans. The genetic architecture of the partial epilepsies is likely to be very complex, reflecting genotypic and phenotypic heterogeneity. Larger meta-analyses are required to identify variants of smaller effect sizes (odds ratio<1.3) or syndrome-specific variants. Further, our results suggest research efforts should also be directed towards identifying the multiple rare variants likely to account for at least part of the heritability of the partial epilepsies. Data emerging from genome-wide association-studies will be valuable during the next serious challenge of interpreting all the genetic variation emerging from whole-genome sequencing studies.
ESTHER : Kasperaviciute_2010_Brain_133_2136
PubMedSearch : Kasperaviciute_2010_Brain_133_2136
PubMedID: 20522523